Cholestyramine Dosing for Pediatric Pruritus
For pediatric patients with cholestatic pruritus, start cholestyramine at 240 mg/kg/day of anhydrous resin divided into 2-3 doses, with a maximum of 8 g/day, titrating based on response and tolerance 1.
Dosing Algorithm
Initial Dosing
- Starting dose: 240 mg/kg/day of anhydrous cholestyramine resin
- Divided into: 2-3 doses per day
- Maximum daily dose: 8 g/day (not to exceed)
- Important conversion: 44.4 mg of anhydrous cholestyramine resin = 100 mg of Cholestyramine for Oral Suspension 1
Practical Administration
- Mix powder with at least 2-3 ounces of water or non-carbonated beverage—never give dry powder 1
- Can also mix with highly fluid soups or pulpy fruits (applesauce, crushed pineapple) 1
- Administer at mealtimes when possible 1
Critical Timing Considerations
Space cholestyramine at least 4 hours away from other medications to avoid binding and reduced absorption 2. This is particularly important for:
- Ursodeoxycholic acid (UDCA)
- Fat-soluble vitamins (A, D, E, K)
- Any other concurrent medications
The guideline evidence strongly emphasizes this 4-hour separation as essential 2.
Position in Treatment Algorithm
Cholestyramine serves as first-line therapy for cholestatic pruritus in both adults and children 2. The EASL guidelines from 2009 establish this hierarchy, which remains the standard approach:
- First-line: Cholestyramine (4 g up to four times daily in adults; weight-based in children)
- Second-line: Rifampicin (150-600 mg daily)
- Third-line: Naltrexone (25-50 mg daily)
- Fourth-line: Sertraline (up to 100 mg daily)
Important Safety Considerations
Fat-Soluble Vitamin Supplementation
Long-term cholestyramine use requires concomitant supplementation with water-miscible or parenteral forms of vitamins A, D, E, and K 1. This is particularly critical in:
- Pregnant patients
- Nursing mothers
- Growing children with chronic cholestasis
The FDA label explicitly warns that cholestyramine interferes with normal fat digestion and absorption 1.
Monitoring Requirements
- Monitor for fat-soluble vitamin deficiency
- Regular prenatal supplementation may be inadequate in pregnancy 1
- Assess response and tolerance with gradual dose titration 1
Evidence Quality and Context
The pediatric dosing recommendation comes directly from the FDA drug label 1, which cites standard medical texts for the 240 mg/kg/day dosing. While this represents the official guidance, the label acknowledges that "an optimal dosage schedule has not been established" and that "the effects of long-term drug administration, as well as its effect in maintaining lowered cholesterol levels in pediatric patients, are unknown" 1.
The EASL guidelines 2 provide strong evidence (Level II-2/B1) for cholestyramine as first-line therapy, though these recommendations are primarily based on adult data. Research evidence confirms cholestyramine's safety and documented efficacy in pediatric cholestatic pruritus 3, 4.
Common Pitfalls to Avoid
- Giving dry powder: Always mix with liquid—aspiration risk and poor palatability
- Inadequate medication spacing: Failure to separate from other drugs by 4 hours reduces efficacy of both cholestyramine and concurrent medications
- Forgetting vitamin supplementation: Long-term use without fat-soluble vitamin replacement leads to deficiency
- Premature escalation: Ensure adequate trial of cholestyramine before moving to second-line agents like rifampicin
Newer Alternatives in Specific Populations
For children with Alagille syndrome specifically, the 2024 EASL guidelines 5 now support ileal bile acid transporter (IBAT) inhibitors like maralixibat (380 μg/kg once daily) and odevixibat as effective alternatives, with statistically significant reductions in pruritus demonstrated in phase III trials. However, cholestyramine remains the established first-line option across all pediatric cholestatic conditions.